Related Experiment Video
Updated: Oct 2, 2025

Teasing Out the Interplay Between Natural Killer Cells and Nociceptor Neurons
Published on: June 30, 2022
[Inhibition of TRPV2 Channel Activation by NK-4, a Cryptocyanine Dye]
Satomi Koya-Miyata1, Keizo Kohno1, Takashi Morimoto1
1Development Section, Pharmaceutical Ingredients Department, Personal Healthcare Division, Hayashibara Co., Ltd.
Abstract:
Transient receptor potential vanilloid 2 (TRPV2) channels are expressed and play functional roles in various immune cells. Physical stimuli leading to TRPV2 activation causes mast cell degranulation. Besides their roles in immune cells, it has been shown that TRPV2 channels are pathophysiologically relevant to degenerative muscular diseases such as dilated cardiomyopathy and muscular dystrophy. Hence, development of drug candidates that inhibit human TRPV2 activation is an urgent matter. NK-4, a cryptocyanine dye, inhibited agonist-induced TRPV2 activity in mouse TRPV2-transfected HEK293 cells. However, it remains unclear whether NK-4 exerts regulatory effects on the activation of human TRPV2 channels. In this study, we show that NK-4 inhibits intracellular Ca2+ increase in human TRPV2-transfected HEK293 cells preactivated with a TRPV2 agonist. The inhibitory effect of NK-4 (IC50=0.27 μM) on human TRPV2 activation was 74-fold stronger than that on mouse TRPV2 activation (IC50=20 μM). NK-4 also inhibited the agonist-induced TRPV2 expression at the plasma membrane, when the human TRPV2-expressing cells were stimulated with the agonist in the presence of NK-4. These results suggest that NK-4 abrogates the agonist-induced signaling events leading to human TRPV2 activation. Furthermore, TRPV2 agonist caused degranulation of RBL-2H3 cells, which represents a phenomenon related to physical urticarias. NK-4 suppressed the release of β-hexosaminidases upon degradation with IC50 of 1.9 μM, 35-fold lower than that determined with an anti-allergic drug, Epinastine. Our results suggest that NK-4 would be a potential therapeutic strategy to resolve dilated cardiomyopathy and its associated heart failure as well as physical urticarias.
Insights
NK-4 effectively inhibits human Transient Receptor Potential Vanilloid 2 (TRPV2) channel activation, showing potential for treating conditions like dilated cardiomyopathy and physical urticarias.
Area of Science:
- Pharmacology
- Molecular Biology
- Immunology
Background:
- Transient Receptor Potential Vanilloid 2 (TRPV2) channels are crucial in immune cells and implicated in degenerative muscular diseases.
- Inhibition of human TRPV2 activation is a therapeutic target for conditions like dilated cardiomyopathy and physical urticarias.
Purpose of the Study:
- To investigate the inhibitory effects of NK-4 on human TRPV2 channel activation.
- To evaluate NK-4's therapeutic potential for TRPV2-related diseases.
Main Methods:
- HEK293 cells transfected with human TRPV2 were used to assess NK-4's inhibition of agonist-induced intracellular Ca2+ increase.
- TRPV2 expression at the plasma membrane was analyzed.
- RBL-2H3 mast cells were used to evaluate NK-4's effect on degranulation.
Main Results:
- NK-4 significantly inhibited human TRPV2 activation with an IC50 of 0.27 μM, demonstrating 74-fold greater potency than on mouse TRPV2.
- NK-4 reduced agonist-induced TRPV2 plasma membrane expression.
- NK-4 suppressed mast cell degranulation (IC50 = 1.9 μM), outperforming Epinastine.
Conclusions:
- NK-4 is a potent inhibitor of human TRPV2 activation, suggesting its potential as a therapeutic agent.
- NK-4 may offer a novel treatment strategy for dilated cardiomyopathy, heart failure, and physical urticarias.

